Indications for ICD and cardiac resynchronization therapy for prevention of sudden cardiac death

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 2, 2009, Pages 181-195

  Das, Mithilesh ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac resynchronization therapy; Implantable cardioverter defibrillator; Sudden cardiac death

Indexed keywords

ALDOSTERONE ANTAGONIST; AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO;

BIOMEDICAL TECHNOLOGY ASSESSMENT; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DEFIBRILLATION; DEFIBRILLATOR; GENETIC DISORDER; HEALTH CARE COST; HEART AMYLOIDOSIS; HEART ARRHYTHMIA; HEART ASSIST DEVICE; HEART MUSCLE ISCHEMIA; HEART RIGHT VENTRICLE DYSPLASIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE PACING; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MORTALITY; PRIMARY PREVENTION; PROGNOSIS; REVIEW; SECONDARY PREVENTION; SUDDEN DEATH; SYNCOPE; TREATMENT INDICATION; CARDIOMYOPATHY; ECONOMICS; HEART FAILURE; HEART PACING; METHODOLOGY; RISK FACTOR; SURVIVAL RATE;

ARRHYTHMIAS, CARDIAC; CARDIAC PACING, ARTIFICIAL; CARDIOMYOPATHIES; CLINICAL TRIALS AS TOPIC; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; HEART FAILURE; HUMANS; RISK FACTORS; SURVIVAL RATE;

EID: 64749086881     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.7.2.181     Document Type: Review

References (55)

1. Myerburg RJ, Interian A Jr, Mitrani RM, Kessler KM, Castellanos A. Frequency of sudden cardiac death and profiles of risk. Am. J. Cardiol. 80(5B), 10F-19F (1997).
2. Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death: epidemiology, transient risk, and intervention assessment. Ann. Intern. Med. 119(12), 1187-1197 (1993).
3. Podrid PJ, Myerburg RJ. Epidemiology and stratification of risk for sudden cardiac death. Clin. Cardiol. 28(11 Suppl. 1), I3-I11 (2005).
4. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N. Engl. J. Med. 345(20), 1473-1482 (2001).
5. Zipes DP. Epidemiology and mechanisms of sudden cardiac death. Can. J. Cardiol. 21 (Suppl. A), 37-40 (2005).
6. Hilleman DE, Bauman AL. Role of antiarrhythmic therapy in patients at risk for sudden cardiac death: an evidence-based review. Pharmacotherapy 21(5), 556-575 (2001).
7. Mirowski M, Reid PR, Mower MM et al. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N. Engl. J. Med. 303(6), 322-324 (1980).
8. Zipes DP, Camm AJ, Borggrefe M et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death, a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to develop Guidelines for Management of patients with ventricular arrhythmias and the prevention of sudden cardiac death), developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114(10), e385-e484 (2006).
9. Bardy GH, Lee KL, Mark DB et al. Amiodarone or an implantable cardioverter - defibrillator for congestive heart failure. N. Eng. J. Med. 352(3), 225-237 (2005).
10. Abraham WT, Fisher WG, Smith AL et al. Cardiac resynchronization in chronic heart failure. N. Engl. J. Med. 346(24), 1845-1853 (2002).
11. Gras D, Leclercq C, Tang AS, Bucknall C, Luttikhuis HO, Kirstein-Pedersen A. Cardiac resynchronization therapy in advanced heart failure the multicenter InSync clinical study. Eur. J. Heart Fail. 4(3), 311-320 (2002).
12. Linde C, Leclercq C, Rex S et al. Long-term benefits of biventricular pacing in congestive heart failure, results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. J. Am. Coll. Cardiol. 40(1), 111-118 (2002).
13. Young JB, Abraham WT, Smith AL et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure, the MIRACLE ICD Ttial. JAMA 289(20), 2685-2694 (2003).
14. Bristow MR, Saxon LA, Boehmer J et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N. Engl. J. Med. 350(21), 2140-2150 (2004).
15. Cleland JG, Daubert JC, Erdmann E et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N. Engl. J. Med. 352(15), 1539-1549 (2005).
16. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N. Engl. J. Med. 337(22), 1576-1583 (1997).
17. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest, the Cardiac Arrest Study Hamburg (CASH). Circulation 102(7), 748-754 (2000).
18. Connolly SJ, Gent M, Roberts RS et al. Canadian implantable defibrillator study (CIDS), a randomized trial of the implantable cardioverter - defibrillator against amiodarone. Circulation 101(11), 1297-1302 (2000).
19. Connolly SJ, Hallstrom AP, Cappato R et al. Meta-analysis of the implantable cardioverter - defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur. Heart J. 21(24), 2071-2078 (2000).
20. Nademanee K, Veerakul G, Mower M et al. Defibrillator Versus β-Blockers for Unexplained Death in Thailand (DEBUT), a randomized clinical trial. Circulation 107(17), 2221-2226 (2003).
21. Lau EW, Griffith MJ, Pathmanathan RK et al. The Midlands Trial of Empirical Amiodarone versus Electrophysiology-guided Interventions and Implantable Cardioverter - defibrillators (MAVERIC), a multi-centre prospective randomised clinical trial on the secondary prevention of sudden cardiac death. Europace 6(4), 257-266 (2004).
22. Epstein AE, DiMarco JP, Ellenbogen KA et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities, a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the ACC/ AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices), developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 117(21), e350-e408 (2008).
23. Moss AJ, Zareba W, Hall WJ et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced. N. Engl. J. Med. 346(12), 877-883 (2002).
24. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G; Multicenter Unsustained Tachycardia Trial Investigators. A randomized study of the prevention of sudden death in patients with coronary artery disease. N. Engl. J. Med. 341(25), 1882-1890 (1999).
25. Moss AJ, Hall WJ, Cannom DS et al.; Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N. Engl. J. Med. 335(26), 1933-1940 (1996).
26. Hohnloser SH, Kuck KH, Dorian P et al. Prophylactic use of an implantable cardioverter - defibrillator after acute myocardial infarction. N. Engl. J. Med. 351(24), 2481-2488 (2004).
27. Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N. Engl. J. Med. 337(22), 1569-1575 (1997).
28. Kunavarapu C, Bloomfield DM. Role of noninvasive studies in risk stratification for sudden cardiac death. Clin. Cardiol. 27(4), 192-197 (2004).
29. Solomon SD, Zelenkofske S, McMurray JJ et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N. Engl. J. Med. 352(25), 2581-2588 (2005).
30. Lee DS, Green LD, Liu PP et al. Effectiveness of implantable defibrillators for preventing arrhythmic events and death, a meta-analysis. J. Am. Coll. Cardiol. 41(9), 1573-1582 (2003).
31. Bansch D, Antz M, Boczor S et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy, the Cardiomyopathy Trial (CAT). Circulation 105(12), 1453-1458 (2002).
32. Strickberger SA, Hummel JD, Bartlett TG et al. Amiodarone versus implantable cardioverter - defibrillator, randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia - AMIOVIRT. J. Am. Coll. Cardiol. 41(10), 1707-1712 (2003).
33. Kadish A, Dyer A, Daubert JP et al. Prophylactic defibriliator implantation in patients with nonischemic dilated cardiomyopathy. N. Engl. J. Med. 350(21), 2151-2158 (2004).
34. Kadish A, Schaechter A, Subacius H et al. Patients with recently diagnosed nonischemic cardiomyopathy benefit from implantable cardioverter - defibrillators. J. Am. Coll. Cardiol. 47(12), 2477-2482 (2006).
35. Knight BP, Goyal R, Pelosi F et al. Outcome of patients with nonischemic dilated cardiomyopathy and unexplained syncope treated with an implantable defibrillator. J. Am. Coll. Cardiol. 33(7), 1964-1970 (1999).
36. Ellenbogen KA, Levine JH, Berger RD et al. Are implantable cardioverter - defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy? Circulation 113(6), 776-782 (2006).
37. Cesario DA, Dec GW. Implantable cardioverter - defibrillator therapy in clinical practice. J. Am. Coll. Cardiol. 47(8), 1507-1517 (2006).
38. Zipes DP, Camm AJ, Borggrefe M et al. [Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Executive summary]. Rev. Esp. Cardiol. 59(12), 1328 (2006).
39. Priori SG, Napolitano C, Gisparini M et al. Natural history of Brugada syndrome, insights for risk stratification and management. Circulation 105(11), 1342-1347 (2002).
40. Sherrid MV. Pathophysiology and treatment of hypertrophic cardiomyopathy. Prog. Cardiovasc. Dis. 49(2), 123-151 (2006).
41. Maron BJ, Spirito P, Shen WK et al. Implantable cardioverter - defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 298(4), 405-412 (2007).
42. Maron BJ, Shen WK, Link MS et al. Efficacy of implantable cardioverter - defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N. Engl. J. Med. 342(6), 365-373 (2000).
43. Piccini JP, Dalal D, Roguin A et al. Predictors of appropriate implantable defibrillator therapies in patients with arrhythmogenic right ventricular dysplasia. Heart Rhythm 2(11), 1188-1194 (2005).
44. McAlister FA, Ezekowitz J, Dryden DM et al. Cardiac resynchronization therapy and implantable cardiac defibrillators in left ventricular systolic dysfunction. Evid. Rep. Technol. Assess. (152), 1-199 (2007).
45. Sweeney MO, Bank AJ, Nsah E et al. Minimizing ventricular pacing to reduce atrial fibrillation in sinus-node disease. N. Engl. J. Med. 357(10), 1000-1008 (2007).
46. Steinberg JS, Fischer A, Wang P et al. The clinical implications of cumulative right ventricular pacing in the multicenter automatic defibrillator trial II. J. Cardiovasc. Electrophysiol. 16(4), 359-365 (2005).
47. Friedman PA, Jalal S, Kaufman S et al. Effects of a rate smoothing algorithm for prevention of ventricular arrhythmias, results of the Ventricular Arrhythmia Suppression Trial (VAST). Heart Rhythm 3(5), 573-580 (2006).
48. Milasinovic G, Sperzel J, Smith TW et al. Reduction of RV pacing by continuous optimization of the AV interval. Pacing Clin. Electrophysiol. 29(4), 406-412 (2006).
49. Sears SF Jr, Conti JB, Curtis AB, Saia TL, Foote R, Wen F. Affective distress and implantable cardioverter - defibrillators, cases for psychological and behavioral interventions. Pacing Clin. Electrophysiol. 22(12), 1831-1834 (1999).
50. Maisel WH, Moynahan M, Zuckerman BD et al. Pacemaker and ICD generator malfunctions, analysis of Food and Drug Administration annual reports. JAMA 295(16), 1901-1906 (2006).
51. Epstein AE, Baessler CA, Curtis et al. Addendum to "Personal and public safety issues related to arrhythmias that may affect consciousness, implications for regulation and physician recommendations, a medical/scientific statement from the American Heart Association and the North American Society of Pacing and Electrophysiology", public safety issues in patients with implantable defibrillators, a scientific statement from the American Heart Association and the Heart Rhythm Society. Circulation 115(9), 1170-1176 (2007).
52. Chow T, Kereiakes DJ, Onufer J et al. Does microvolt T-wave alternans testing predict ventricular tachyarrhythmias in patients with ischemic cardiomyopathy and prophylactic defibrillators? The MASTER (Microvolt T Wave Alternans Testing for Risk Stratification of Post-Myocardial Infarction Patients) trial. J. Am. Coll. Cardiol. 52(20), 1607-1615 (2008).
53. Gold MR, Ip JH, Costantini O et al. Role of microvolt T-wave alternans in assessment of arrhythmia vulnerability among patients with heart failure and systolic dysfunction. Primary results from the T-wave alternans sudden cardiac death in heart failure trial substudy. Circulation 118(20), 2022-2028 (2008).
54. Costantini O. The Alternans Before Cardioverter - defibrillator (ABCD) trial, a non-invasive strategy for primary prevention of sudden cardiac death using T wave alternans. American Heart Association 2006 Scientific Sessions. Chicago, IL, USA, 12-15 November 2006.
55. Gold MR, Bloomfield DM, Anderson KP et al. A comparison of T-wave alternans, signal averaged electrocardiography and programmed ventricular stimulation for arrhythmia risk stratification. J. Am. Coll. Cardiol. 36(7), 2247-2253 (2000).